June 20 (Reuters) - Wegovy maker Novo Nordisk (NOVOb.CO) on Tuesday said it had sued some medical spas and wellness clinics in the United States for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss and diabetes drugs.
The Danish drugmaker said it had filed federal court lawsuits in states including New York, Florida, Tennessee and Texas, accusing the spas of selling unapproved variations of its drugs.
Novo Nordisk asked the courts for orders blocking the sales of the unauthorized drugs and an unspecified amount of money damages.
Four of the companies named in the lawsuits in Florida, Texas and Tennessee did not immediately respond to requests for comment.
Reporting by Nikolaj Skydsgaard and Blake Brittain; Editing by Ed Osmond and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.
Persons:
Eli Lilly, Danish drugmaker, Nikolaj Skydsgaard, Blake Brittain, Ed Osmond, Alexander Smith
Organizations:
Novo Nordisk, U.S . Food, Drug Administration, FDA, Barclays, Nordisk, Thomson
Locations:
United States, U.S, Danish, New York , Florida , Tennessee, Texas, Florida , Texas, Tennessee